158 related articles for article (PubMed ID: 37051229)
1. Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders.
John J; Chen SMY; Woolaver RA; Ge H; Vashisht M; Huang Z; Chen Z; Wang JH
Front Immunol; 2023; 14():1100520. PubMed ID: 37051229
[TBL] [Abstract][Full Text] [Related]
2. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.
John J; Woolaver RA; Popolizio V; Chen SMY; Ge H; Krinsky AL; Vashisht M; Kramer Y; Chen Z; Wang JH
Front Immunol; 2022; 13():992630. PubMed ID: 36330507
[TBL] [Abstract][Full Text] [Related]
3. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes.
Ge H; Ferris RL; Wang JH
Clin Cancer Res; 2023 Feb; 29(3):647-658. PubMed ID: 36315045
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
[TBL] [Abstract][Full Text] [Related]
6. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
[TBL] [Abstract][Full Text] [Related]
7. T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection.
Chang YM; Wieland A; Li ZR; Im SJ; McGuire DJ; Kissick HT; Antia R; Ahmed R
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759317
[TBL] [Abstract][Full Text] [Related]
8. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.
Kidman J; Zemek RM; Sidhom JW; Correa D; Principe N; Sheikh F; Fear VS; Forbes CA; Chopra A; Boon L; Zaitouny A; de Jong E; Holt RA; Jones M; Millward MJ; Lassmann T; Forrest ARR; Nowak AK; Watson M; Lake RA; Lesterhuis WJ; Chee J
Oncoimmunology; 2024; 13(1):2345859. PubMed ID: 38686178
[TBL] [Abstract][Full Text] [Related]
10. Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
Ham B; Kim SY; Kim YA; Han D; Park T; Cha S; Jung S; Kim JH; Park G; Gong G; Lee HJ; Shin J
Br J Cancer; 2024 May; ():. PubMed ID: 38750113
[TBL] [Abstract][Full Text] [Related]
11. T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients.
Park IA; Rajaei H; Kim YA; Lee H; Lee H; Seo JH; Heo SH; Song IH; Gong G; Lee HJ
Immunol Res; 2020 Oct; 68(5):233-245. PubMed ID: 32886262
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S
Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535
[TBL] [Abstract][Full Text] [Related]
13. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
14. Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors.
Chen Z; John J; Wang JH
Front Oncol; 2022; 12():995434. PubMed ID: 36330485
[TBL] [Abstract][Full Text] [Related]
15. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
17. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
18. Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma.
Kato T; Kiyotani K; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya Y; Wang C; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N; Uemura M
Oncoimmunology; 2021 Jan; 10(1):1862948. PubMed ID: 33537170
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4
Servaas NH; Zaaraoui-Boutahar F; Wichers CGK; Ottria A; Chouri E; Affandi AJ; Silva-Cardoso S; van der Kroef M; Carvalheiro T; van Wijk F; Radstake TRDJ; Andeweg AC; Pandit A
J Autoimmun; 2021 Feb; 117():102574. PubMed ID: 33307312
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of low avidity tumor-specific CD8
Sugiyarto G; Lau D; Hill SL; Arcia-Anaya D; Boulanger DSM; Parkes E; James E; Elliott T
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
